A Database Study to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrix™ in Manitoba, Canada

CompletedOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

December 31, 2015

Conditions
Multiple Sclerosis
Interventions
OTHER

Exposed to Arepanrix™ Cohort

Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected..

OTHER

Unexposed to Arepanrix™ Cohort

Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Manitoba

OTHER

NCT02367222 - A Database Study to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrix™ in Manitoba, Canada | Biotech Hunter | Biotech Hunter